BITESIZE: New Study: Why Did This Drug Lower Cholesterol But Not Heart Plaque?

About this episode

Dr. Bret Scher discusses a new study on Olezarsen and its implications for treating cardiovascular disease.

Lower triglycerides, lower remnant cholesterol, lower ApoB. Zero change in coronary artery plaque. A new clinical trial is forcing a bigger conversation about how we treat cardiovascular disease. The drug was Olezarsen, an APOC3 inhibitor. The blood work looked impressive. The heart scans did not. So why would lowering well-established cardiovascular risk factors fail to move the needle on plaque? Dr. Bret Scher argues there's a critical difference between what we want to fix and how we go about fixing it. Lowering a number with a drug is not the same as addressing the underlying metabolic dysfunction that caused that number to be high in the first place. In this video, you'll learn: What the Olezarsen trial actually showed and why the results matter Why elevated triglycerides often signal deeper metabolic dysfunction and insulin resistance How this same drug-first thinking plays out in type 2 diabetes, hypertension, and weight management Why narrowing our focus to "fix the number" can keep us from healing the whole system How metabolic medicine reframes the conversation around root causes This isn't an argument against medication. Responsible drug use has an important place in…

People in this episode

Host: Dr. Bret Scher

Topics covered

• cholesterol
• cardiovascular disease
• metabolic dysfunction
• insulin resistance
• drug treatment
• lifestyle changes

Keywords

• cholesterol
• triglycerides
• coronary artery plaque
• metabolic health
• insulin resistance
• cardiovascular risk factors
• type 2 diabetes
• hypertension
• weight management

Mentioned in this episode

Organizations: APOC3

Products: Olezarsen

More episodes of Metabolic Mind

• BITESIZE: The New Protein Guidelines Reignited the Plant vs. Animal Debate · June 12, 2026 · 7 min
• BITESIZE: Omega-3 Supplements and Cognitive Decline? Here’s the Full Story · June 10, 2026 · 8 min
• Whole-Person Psychiatry Is Changing Mental Health Care—with Meru Health’s Kristian Ranta · June 8, 2026 · 31 min
• New Study from 25-Year Eating Disorder Expert · June 5, 2026 · 36 min
• First Keto Trial for Anorexia Nervosa: 72% Showed Recovery · June 3, 2026 · 4 min
• Keto as an Adjunct to CBTp? Nicole Laurent Explains · May 29, 2026 · 23 min